Compare CME & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CME | REGN |
|---|---|---|
| Founded | 1898 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.9B | 68.8B |
| IPO Year | 2002 | 1995 |
| Metric | CME | REGN |
|---|---|---|
| Price | $270.55 | $826.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 25 |
| Target Price | $307.42 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 2.1M | 762.4K |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.95% | 0.55% |
| EPS Growth | ★ 15.41 | 8.19 |
| EPS | 6.06 | ★ 18.95 |
| Revenue | ★ $6,520,600,000.00 | $5,872,227,000.00 |
| Revenue This Year | $10.08 | $12.45 |
| Revenue Next Year | $4.40 | $10.13 |
| P/E Ratio | ★ $44.05 | $44.37 |
| Revenue Growth | 6.37 | ★ 20.82 |
| 52 Week Low | $218.31 | $541.00 |
| 52 Week High | $329.16 | $844.92 |
| Indicator | CME | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.75 | 76.46 |
| Support Level | $262.27 | $732.04 |
| Resistance Level | $279.39 | N/A |
| Average True Range (ATR) | 5.97 | 18.94 |
| MACD | 0.33 | 2.88 |
| Stochastic Oscillator | 88.53 | 83.92 |
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indexes, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.